Cited by 250Immunotoxicology and immune responsesMonoclonal and Polyclonal Antibodies ResearchAnimal testing and alternatives

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Open access

Brennan, Frank R., Morton, Laura Dill, Spindeldreher, Sebastian, Kiessling, Andrea, Allenspach, Roy, Hey, Adam, Müller, Patrick, Frings, Werner, Sims, Jennifer·2010·mAbs

DOI 10.4161/mabs.2.3.11782PMC PMC2881251

Open this paper in CoChat — free account Open PDF

Abstract

Most therapeutic monoclonal antibodies (mAbs) licensed for human use or in clinical development are indicated for treatment of patients with cancer and inflammatory/autoimmune disease and as such, are designed to directly interact with the immune system. A major hurdle for the development and early clinical investigation of many of these immunomodulatory mAbs is their inherent risk for adverse immune-mediated drug reactions in humans such as infusion reactions, cytokine storms, immunosuppression and autoimmunity. A thorough understanding of the immunopharmacology of a mAb in humans and animals is required to both anticipate the clinical risk of adverse immunotoxicological events and to select a safe starting dose for first-in-human (FIH) clinical studies. This review summarizes the most common adverse immunotoxicological events occurring in humans with immunomodulatory mAbs and outlines non-clinical strategies to define their immunopharmacology and assess their immunotoxic potential, as well as reduce the risk of immunotoxicity through rational mAb design. Tests to assess the relative risk of mAb candidates for cytokine release syndrome, innate immune system (dendritic cell) activation and immunogenicity in humans are also described. The importance of selecting a relevant and sensitive toxicity species for human safety assessment in which the immunopharmacology of the mAb is similar to that expected in humans is highlighted, as is the importance of understanding the limitations of the species selected for human safety assessment and supplementation of in vivo safety assessment with appropriate in vitro human assays. A tiered approach to assess effects on immune status, immune function and risk of infection and cancer, governed by the mechanism of action and structural features of the mAb, is described. Finally, the use of immunopharmacology and immunotoxicity data in determining a minimum anticipated biologic effect Level (MABEL) and in the selection of safe human starting dose is discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.4161/mabs.2.3.11782

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. S., Fischkoff, S. A., & Chartash, E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,754
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0207 · Cited by 1,483
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
Casadevall, N., Nataf, J., Viron, B. M., Kolta, A. M., Kiladjian, J., Martin-Dupont, P., Michaud, P. A., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,244
Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice
Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J.-C., Lanzavecchia, A., & Manz, M. G. (2004) · Science · doi:10.1126/science.1093933 · Cited by 989
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
Sturniolo, T., Bono, E. B., Ding, J., Raddrizzani, L., Tuereci, O., Şahin, U., Braxenthaler, M., Gallazzi, F., Protti, M. P., Sinigaglia, F., et al. (1999) · Nature Biotechnology · doi:10.1038/9858 · Cited by 743

Flagged first, then by citations

Show all 115 references

Research works printed but not linked: 6

Menter A, 2009, Cutis, 84, 14
CDER/FDA, 2005, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
EMEA/CHMP, 2007, Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products
Kang SP, 2007, J Support Oncol, 5, 451
Bugelski PJ, 2008, Slide Presentation, FDA Immunotoxicology Symposium, Cytokine Release: What Does It Mean?
Strauss G, 1994, Immunogenetics, 40, 104

Sorted by citations

Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 937
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells
Zhu, X., Badawi, M. A., Pomeroy, S. M., Sutaria, D. S., Xie, Z., Baek, A., Jiang, J., Elgamal, O. A., Mo, X. M., Perle, K. L., et al. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1324730 · Cited by 599
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
Dobrovolskaia, M. A., & McNeil, S. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.025 · Cited by 324
Clinical cancer immunotherapy: Current progress and prospects
Liu, C., Yang, M., Zhang, D., Chen, M., & Zhu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961805 · Cited by 261
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Wang, S.-L., Ohrmund, L., Hauenstein, S. I., Salbato, J., Reddy, R., Monk, P., Lockton, S., LING, N. C., & Singh, S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.06.002 · Cited by 210
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S. T., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 186
Self-citation
Human IgG4: a structural perspective
Davies, A. M., & Sutton, B. J. (2015) · Immunological Reviews · doi:10.1111/imr.12349 · Cited by 176
The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice
Yoshida, S., Nakagami, H., Hayashi, H., Ikeda, Y., Sun, J., Tenma, A., Tomioka, H., Kawano, T., Shimamura, M., Morishita, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16347-w · Cited by 161
Immunogenicity of Protein Pharmaceuticals
Dingman, R. K., & Balu‐Iyer, S. V. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.014 · Cited by 162
Overview of Antibody Drug Delivery
Awwad, S., & Angkawinitwong, U. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030083 · Cited by 159
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 166
Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes
Rojko, J. L., Evans, M. G., Price, S. A., Han, B., Waine, G. J., DeWitte, M., Haynes, J. A., Freimark, B. D., Martin, P. L., Raymond, J. T., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314526475 · Cited by 150
Biocompatibility of Biomaterials for Nanoencapsulation: Current Approaches
Witika, B. A., Makoni, P. A., Matafwali, S. K., Chabalenge, B., Mwila, C., Kalungia, A. C., Nkanga, C. I., Bapolisi, A. M., & Walker, R. B. (2020) · Nanomaterials · doi:10.3390/nano10091649 · Cited by 150
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
van Meer, P. J. K., Kooijman, M., Brinks, V., Wied, C. C. G., Lima, B. S., Moors, E. H. M., & Schellekens, H. (2013) · mAbs · doi:10.4161/mabs.25234 · Cited by 132
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
Miao, L., Wang, Y., Lin, C. M., Xiong, Y., Chen, N., Zhang, L., Kim, W. Y., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.027 · Cited by 119
Theranostic nanoparticles with disease-specific administration strategies
Zhang, P., Li, Y., Tang, W., Zhao, J., Jing, L., & McHugh, K. J. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101335 · Cited by 120
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications
Derer, A., Deloch, L., Rubner, Y., Fietkau, R., Frey, B., & Gaipl, U. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00505 · Cited by 113
Immunogenicity of therapeutic recombinant immunotoxins
Mazor, R., Onda, M., & Pastan, I. H. (2016) · Immunological Reviews · doi:10.1111/imr.12390 · Cited by 110
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
Saber, H., Valle, P. D., Ricks, T. K., & Leighton, J. K. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.09.001 · Cited by 108
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
Lü, J., Lee-Gabel, L., Nadeau, M. C., Ferencz, T. M., & Soefje, S. A. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214538087 · Cited by 104
Drug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 101
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
Ben‐Horin, S., Casteele, N. V., Schreiber, S., & Lakatos, P. L. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.023 · Cited by 94
In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions
Tomar, D. S., Li, L., Broulidakis, M. P., Luksha, N., Burns, C. T., Singh, S. K., & Kumar, S. (2017) · mAbs · doi:10.1080/19420862.2017.1285479 · Cited by 91
Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein
Curtin, F., Perron, H., Kromminga, A., Porchet, H. C., & Lang, A. B. (2014) · mAbs · doi:10.4161/19420862.2014.985021 · Cited by 89
Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment
Iezzi, M. E., Policastro, L., Werbajh, S., Podhajcer, O. L., & Canziani, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00273 · Cited by 84
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules
Harper, J. V., Adams, K. J., Bossi, G., Wright, D. E., Stacey, A., Bedke, N., Martinez-Hague, R., Blat, D., Humbert, L., Buchanan, H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205491 · Cited by 87
Have we overestimated the benefit of human(ized) antibodies?
Getts, D. R., Getts, M. T., McCarthy, D. P., Chastain, E. M. L., & Miller, S. D. (2010) · mAbs · doi:10.4161/mabs.2.6.13601 · Cited by 85
Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
Wang, S.-L., Hauenstein, S. I., Ohrmund, L., Shringarpure, R., Salbato, J., Reddy, R., McCowen, K. M., Shah, S. M., Lockton, S., Chuang, E., et al. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.01.031 · Cited by 81
Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy
Liu, M., Song, W., & Huang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.032 · Cited by 83
Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
Vultaggio, A., Maggi, E., & Matucci, A. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283464bcd · Cited by 73
Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics
Ataie, N., Xiang, J., Cheng, N. N., Brea, E. J., Lu, W. J., Scheinberg, D. A., Liu, C., & Ng, H. L. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.12.002 · Cited by 69
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2873-x · Cited by 64
Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review
van Bussel, M. T. J., Beijnen, J. H., & Brandsma, D. (2019) · BMC Cancer · doi:10.1186/s12885-019-5741-y · Cited by 68
Developability assessment as an early de-risking tool for biopharmaceutical development
Zurdo, J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.3 · Cited by 66
Development of a Cell-Based Assay Measuring the Activation of FcγRIIa for the Characterization of Therapeutic Monoclonal Antibodies
Tada, M., Ishii‐Watabe, A., Suzuki, T., & Kawasaki, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095787 · Cited by 58
Microtools for single-cell analysis in biopharmaceutical development and manufacturing
Love, K. R., Bagh, S., Choi, J. H., & Love, J. C. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.03.001 · Cited by 56
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
Horinouchi, H., Yamamoto, N., Fujiwara, Y., Sekine, I., Nokihara, H., Kubota, K., Kanda, S., Yagishita, S., Wakui, H., Kitazono, S., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0243-5 · Cited by 54
An FDA oncology analysis of immune activating products and first-in-human dose selection
Saber, H., Gudi, R., Manning, M. L., Wearne, E., & Leighton, J. K. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.10.002 · Cited by 53
Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates
Morgan, H., Tseng, S.-Y., Gallais, Y., Leineweber, M., Buchmann, P., Riccardi, S., Nabhan, M., Lo, J., Gani, Z., Szely, N., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00601 · Cited by 56
Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
Barone, G., Barry, A., Bautista, F. J., Brichard, B., Defachelles, A. S., Herd, F., Manzitti, C., Reinhardt, D., Rubio, P., Wieczorek, A., et al. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00469-9 · Cited by 56
A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans
Wolf, B., Morgan, H., Krieg, J., Gani, Z., Milicov, A., Warncke, M., Brennan, F. R., Jones, S., Sims, J., & Kießling, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.018 · Cited by 50
Self-citation
Hypersensitivity Reactions to Biologic Agents
Vultaggio, A., & Castells, M. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.04.008 · Cited by 49
The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
Safety evaluation of biological drugs: What are toxicology studies in primates telling us?
Baldrick, P. (2010) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.10.005 · Cited by 46
Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges
Li, W., Little, N., Park, J., Foster, C. A., Chen, J., & Lu, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00455 · Cited by 46
Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis
Tanaka, H., Yang, G.-X., Iwakoshi, N. N., Knechtle, S. J., Kawata, K., Tsuneyama, K., Leung, P. S. C., Coppel, R. L., Ansari, A. A., Joh, T., et al. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12193 · Cited by 45
Emerging trends and therapeutic applications of monoclonal antibodies
Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 45
Neuro-ophthalmic side effects of molecularly targeted cancer drugs
Bhatti, M. T., & Salama, A. K. S. (2017) · Eye · doi:10.1038/eye.2017.222 · Cited by 43
The importance of early identification of infusion-related reactions to monoclonal antibodies
Cáceres, M. C., Guerrero-Martín, J., Pérez-Civantos, D. V., Palomo‐López, P., Delgado-Mingorance, J. I., & Durán‐Gómez, N. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s204909 · Cited by 42
Effect of growth hormone and IgG aggregates on dendritic cells activation and T‐cells polarization
Gallais, Y., Szely, N., Legrand, F., Leroy, A., Pallardy, M. J., & Turbica, I. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.100 · Cited by 41
Engineered Treg cells: The heir to the throne of immunotherapy
Stucchi, A., Maspes, F., Montee-Rodrigues, E., & Fousteri, G. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102986 · Cited by 43
Nanoparticle‐mediated HMGA1 Silencing Promotes Lymphocyte Infiltration and Boosts Checkpoint Blockade Immunotherapy for Cancer
Wang, Y., Song, W., Hu, M., An, S., Xu, L., Li, J., Kinghorn, K., Liu, R., & Huang, L. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802847 · Cited by 42
Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation
Scott, B. J., Klein, Á., & Wang, J. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.339 · Cited by 40
Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs
Jinesh, S. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0229-0 · Cited by 40
Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13)
Kim, J. S., Kim, S. H., Kwon, B., & Hong, S. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1090312 · Cited by 39
Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know
Silberstein, S., Lenz, R. A., & Xu, C. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12642 · Cited by 39
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors
Gu, Y., & Zhao, Q. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00734-w · Cited by 38
Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices
Morford, L. L., Bowman, C., Blanset, D. L., Bøgh, I. B., Chellman, G. J., Halpern, W., Weinbauer, G. F., & Coogan, T. P. (2011) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20305 · Cited by 37
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials
Sewell, F. R., Chapman, K. L., Baldrick, P., BREWSTER, D. W., Broadmeadow, A., Brown, P. C., Burns‐Naas, L. A., Clarke, J. B., Constan, A., Couch, J. A., et al. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.07.018 · Cited by 37
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
Chien, H.-T., Prior, H. M., Andrews, L., Aerts, L. A. G. J. M. V., Cauvin, A. J., Clarke, D. O., Datta, K., Dempster, M., Dybdal, N. O., Freebern, W. J., et al. (2022) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105329 · Cited by 36
Self-citation
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
Yang, J., He, X., Lv, Q., Jing, J., & Shi, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00726 · Cited by 36
Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa
Higa, L. H., Jerez, H. E., de Farias, M. A., Portugal, R. V., Romero, E. L., & Morilla, M. J. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0437 · Cited by 35
Enhancing immunity during ageing by targeting interactions within the tissue environment
Bracken, O. V., Maeyer, R. P. H. D., & Akbar, A. N. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01126-9 · Cited by 43
GMP-compliant extracellular vesicles derived from umbilical cord mesenchymal stromal cells: manufacturing and pre-clinical evaluation in ARDS treatment
Costa‐Ferro, Z. S. M., Rocha, G. V., da Silva, K. N., Paredes, B. D., Loiola, E. C., Silva, J. D., Santos, J. L. D. S., Dias, R. B., Figueira, C. P., de Oliveira, C. I., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.04.074 · Cited by 36
Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection
Леонидовна, Т. И., Sedova, E. S., Gribova, I. Y., Ivanova, T. I., Vasilev, L. A., Rutovskaya, M. V., Lysenko, A. A., Шмаров, М. М., Logunov, D. Y., Naroditsky, B. S., et al. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.12.021 · Cited by 34
A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies
Flisikowska, T., Egli, J., Flisikowski, K., Stumbaum, M., Küng, E., Ebeling, M., Schmucki, R., Georges, G. J., Singer, T., Kurome, M., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00921-2 · Cited by 33
Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies
Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33
Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17
Landolina, N., & Levi‐Schaffer, F. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13396 · Cited by 33
Considerations for setting occupational exposure limits for novel pharmaceutical modalities
Graham, J. C., Hillegass, J., & Schulze, G. E. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104813 · Cited by 32
Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma
Balaguer, J., Hidalgo, L. G., Hladun, R., Vega, C. M., & Alonso, V. P. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00930-w · Cited by 31
Biologic response modifiers: Indications, implications, and insights
Davis, B. P., & Ballas, Z. K. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.02.013 · Cited by 31
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
Lucas, A. T., Robinson, R., Schorzman, A. N., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2019) · Antibodies · doi:10.3390/antib8010003 · Cited by 31
A review on tumor-targeting liposomes: Fabrication, mechanism and applications
Basak, S., Das, T. K., & Ganguly, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117460 · Cited by 32
Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity
Rosario, J. M. M. D., Smith, M. D., Zaki, K., Risley, P., Temperton, N. J., Engelhardt, O. G., Collins, M. K., Takeuchi, Y., & Hufton, S. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00627 · Cited by 31
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
Hagerty, B. L., Pegna, G. J., Xu, J., Tai, C., & Alewine, C. (2020) · Biomolecules · doi:10.3390/biom10070973 · Cited by 30
Society of Toxicologic Pathology Position Paper on Best Practices on Recovery Studies
Perry, R., Farris, G. M., Bienvenu, J.-G., Dean, C., Foley, G. L., Mahrt, C., & Short, B. G. (2013) · Toxicologic Pathology · doi:10.1177/0192623313481513 · Cited by 30
Redefining Approaches to Asthma
Arron, J. R., Scheerens, H., & Matthews, J. G. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-404717-4.00001-9 · Cited by 29
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
Woo, J., Vierboom, M., Kwon, H., Chao, D. T., Ye, S., Li, J., Lin, K., Tang, I., Belmar, N. A., Hartman, T. E., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4400 · Cited by 27
6thAnnual European Antibody Congress 2010
Beck, A., & Wurch, T. (2011) · mAbs · doi:10.4161/mabs.3.2.14788 · Cited by 27
Advantages ofPapio anubisfor preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28
Poirier, N., Mary, C., Bas‐Bernardet, S. L., Daguin, V., Belarif, L., Chevalier, M., Hervouet, J., Minault, D., Ville, S., Charpy, V., et al. (2014) · mAbs · doi:10.4161/mabs.28375 · Cited by 26
In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies
Brennan, F. R., & Kießling, A. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.02.025 · Cited by 26
Self-citation
TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review
Li, Y., Jiang, W., & Mellins, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968432 · Cited by 23
How Biologics Have Changed the Drug Discovery Landscape
McGonigle, P. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080811 · Cited by 26
A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts
Yoshida, S., Hayashi, H., Kawahara, T., Katsuki, S., Kimura, M., Hino, R., Sun, J., Nakamaru, R., Tenma, A., Toyoura, M., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.325017 · Cited by 30
Investigative safety science as a competitive advantage for Pharma
Moggs, J. G., Moulin, P., Pognan, F., Brees, D., Leonard, M., Busch, S., Cordier, A., Heard, D. J., Kammuller, M. E., Merz, M., et al. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.693914 · Cited by 25
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 28
The Yin and Yang of Immunomodulatory Biologics: Assessing the Delicate Balance between Benefit and Risk
Danilenko, D. M., & Wang, H. (2012) · Toxicologic Pathology · doi:10.1177/0192623311430237 · Cited by 24
Novel therapeutic options for multiple sclerosis
Curtin, F., & Hartung, H. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.865517 · Cited by 26
Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm
Morgulchik, N., Athanasopoulou, F., Chu, E., Lam, Y., & Kamaly, N. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0006 · Cited by 23
COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
Chary, M. A., Barbuto, A. F., Izadmehr, S., Tarsillo, M., Fleischer, E., & Burns, M. M. (2023) · Journal of Medical Toxicology · doi:10.1007/s13181-023-00931-9 · Cited by 25
Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases
Brennan, F. R., Cauvin, A. J., Tibbitts, J., & Wolfreys, A. (2014) · Drug Development Research · doi:10.1002/ddr.21173 · Cited by 23
Self-citation
Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs
Jawa, V., Maamary, J., Swanson, M. D., Zhang, S., & Montgomery, D. L. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.032 · Cited by 22
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
Kanter, J., Brown, C., Norris, C. F., Nair, S. M., Kutlar, A., Manwani, D. G., Shah, N., Tanaka, C., Bodla, S., Sánchez-Ollé, G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008209 · Cited by 22
Development of Antibody-Based Therapeutics
Tabrizi, M. A., Klakamp, S. L., & Bornstein, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3 · Cited by 23
From the Hellstrom paradox toward cancer cure
Hellström, K. E., & Hellström, I. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.11.002 · Cited by 22
Therapeutic potential and toxicological challenges of metal nanoparticles in drug delivery: A comprehensive review
Mehmood, S., Iraqui, S., Ojha, R. K., Sharma, N., & Marlinda, A. R. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102862 · Cited by 24
PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models
Kim, D., Lee, S. S., Moon, H., Park, S. Y., & Lee, H. J. (2020) · Pharmaceuticals · doi:10.3390/ph14010006 · Cited by 21
Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H
Fülöp, T., Mészáros, T., Kozma, G. T., Szebeni, J., & Józsi, M. (2018) · Antibodies · doi:10.3390/antib7010014 · Cited by 21
Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges
Brennan, F. R., Andrews, L., Arulanandam, A. R. N., Blümel, J., Fikes, J., Grimaldi, C. M., Lansita, J. A., Loberg, L. I., MacLachlan, T. K., Milton, M., et al. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.07.009 · Cited by 21
Self-citation
Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
Biteghe, F. A. N., Chalomie, N. E. T., Mungra, N., Vignaux, G., Gao, N., Vergeade, A., Okem, A., Naran, K., Ndong, J. D. L. C., & Barth, S. (2020) · Biomedicines · doi:10.3390/biomedicines8090327 · Cited by 20

Authors: Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J.
Affiliations: Novartis (Switzerland) (CH)
Corresponding author: Brennan, Frank R.
ORCID: Spindeldreher, Sebastian
Hey, Adam
Frings, Werner
Venue: mAbs
Publisher: Informa UK Limited
Published: 2010-05
Volume: 2
Issue: 3
Pages: 233-255
ISSN: 1942-0862 (ISSN-L)
1942-0870
DOI: 10.4161/mabs.2.3.11782
PMC: PMC2881251
OpenAlex: W2044692977
Cited by: 250
References: 115
Citations by year: 2026: 13 · 2025: 12 · 2024: 21 · 2023: 13 · 2022: 14 · 2021: 9 · 2020: 13 · 2019: 15 · 2018: 18 · 2017: 23 · 2016: 16 · 2015: 19 · 2014: 19 · 2013: 22 · 2012: 14
FWCI: 1.15
Type: journal article
Language: en
Open access: gold
doi.org
Locations: mAbs (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Keywords: immunotoxicity, immunopharmacology, cytokine release syndrome, dendritic cell activation, immunogenicity, first-in-human dose selection, immune-related adverse events
MeSH terms: Animals, Antibodies, Monoclonal, Autoimmune Diseases, Clinical Trials as Topic, Dendritic Cells, Drug Evaluation, Preclinical, Humans, Immune System, Neoplasms, Cytokines, Guidelines as Topic, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks